The Asian stock markets have recently experienced a rebound, supported by stronger-than-expected economic data from China and optimism around geopolitical de-escalation in the Middle East. As investors navigate these shifting conditions, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for growth in an otherwise cautious market environment.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Zhaojin Mining Industry (SEHK:1818) |
HK$29.28 |
HK$57.51 |
49.1% |
|
WuXi XDC Cayman (SEHK:2268) |
HK$58.40 |
HK$115.88 |
49.6% |
|
Sichuan New Energy Power (SZSE:000155) |
CN¥16.73 |
CN¥33.02 |
49.3% |
|
MicroPort Scientific (SEHK:853) |
HK$9.08 |
HK$17.95 |
49.4% |
|
Lum Chang Creations (Catalist:LCC) |
SGD0.98 |
SGD1.96 |
50% |
|
Hantech (KOSDAQ:A098070) |
₩43900.00 |
₩85076.23 |
48.4% |
|
Geely Automobile Holdings (SEHK:175) |
HK$23.66 |
HK$46.14 |
48.7% |
|
DIGITAL HEARTS HOLDINGS (TSE:3676) |
¥839.00 |
¥1633.09 |
48.6% |
|
A-tieLtd (TSE:369A) |
¥2619.00 |
¥5123.61 |
48.9% |
|
a2 Milk (NZSE:ATM) |
NZ$8.96 |
NZ$17.34 |
48.3% |
Let’s review some notable picks from our screened stocks.
Overview: Gushengtang Holdings Limited is an investment holding company offering healthcare services in the People’s Republic of China, with a market capitalization of approximately HK$6.34 billion.
Operations: The company’s revenue is primarily derived from the provision of healthcare solutions, amounting to CN¥3.22 billion, and the sale of healthcare products, contributing CN¥29.42 million.
Estimated Discount To Fair Value: 18%
Gushengtang Holdings is trading at HK$28.88, which is 18% below its estimated fair value of HK$35.21, highlighting potential undervaluation based on cash flow analysis. The company reported increased earnings and revenue for 2025, with net income rising to CNY 352.77 million from CNY 306.78 million the previous year. Despite moderate earnings growth forecasts of 14.9% annually, the company’s revenue growth outpaces the Hong Kong market average, suggesting robust future performance prospects amidst recent executive changes and strategic investments.
Overview: Nanjing Vazyme Biotech Co., Ltd provides technology solutions in life science, biomedicine, and in vitro diagnostics with a market cap of approximately CN¥7.85 billion.
Operations: Nanjing Vazyme Biotech Co., Ltd generates revenue through its offerings in life science, biomedicine, and in vitro diagnostics.
Estimated Discount To Fair Value: 39.2%
Nanjing Vazyme Biotech is trading at CNY 19.73, significantly below its estimated fair value of CNY 32.45, indicating undervaluation based on cash flows. The company reported Q1 2026 sales of CNY 320.65 million and net income of CNY 4.18 million, showing improvement from the previous year. With forecasted annual revenue growth of 25.7%, outpacing the Chinese market average, and expected profitability within three years, it presents a compelling investment case despite current dividend sustainability concerns.
Overview: ACES Electronics Co., Ltd. is engaged in the research, development, manufacture, and sale of electronic connectors across Taiwan, China, the Philippines, the United States, and other international markets with a market cap of NT$13.16 billion.
Operations: The company’s revenue is primarily derived from its Connector Department, contributing NT$6.78 billion, followed by the Cables Segment at NT$2.50 billion and the Metal Stamping Department at NT$1.98 billion.
Estimated Discount To Fair Value: 17.1%
ACES Electronics is trading at NT$77.8, below its estimated future cash flow value of NT$93.89, suggesting undervaluation. Recent earnings show strong growth with net income rising to NT$661.19 million from NT$344.06 million year-on-year, driven by revenue increases to NT$10,859.56 million from NT$9,770.9 million. Despite a low forecasted return on equity and unsustainable dividend coverage by free cash flows, the company expects significant earnings and revenue growth exceeding market averages over the next three years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:2273 SHSE:688105 and TWSE:3605.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
















